Compare Nasdaq Inc (NDAQ) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance

Nasdaq (NDAQ) trades at $93.48, down 0.86% on the day, with strong technical momentum showing a bullish moving average signal despite overbought RSI conditions. The company demonstrates robust fundamentals with 2025 revenue of $8.26B and net income of $1.79B, representing a 21.64% profit margin. Recent earnings beats and the launch of AI-powered Calypso platform highlight operational strength. Analyst consensus remains strongly bullish with a $110.43 price target, representing 18% upside potential from current levels.

NDAQ presents a compelling investment case with consistent earnings outperformance, strong profitability metrics, and strategic AI integration driving growth. However, elevated valuation multiples (P/E 27.25) and potential market volatility from exchange operations pose risks. The stock's technical positioning near resistance at $95 requires monitoring, but institutional support and positive analyst sentiment suggest continued upside potential for long-term investors.

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.